Skip to main
ALZN

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has reported positive top-line results from its clinical studies in June 2023, reflecting promising progress in its development of innovative therapies for neurodegenerative diseases and psychiatric disorders. The company's proprietary drug candidates, AL001 and AL002, highlight its commitment to addressing significant unmet medical needs, particularly in Alzheimer's treatment. The current valuation is deemed attractive, with substantial growth potential indicated by net present value analyses, positioning Alzamend Neuro favorably for future investment.

Bears say

Alzamend Neuro Inc has reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which notably deviates from earlier estimates of $(0.69). This significant loss underscores the company's ongoing financial challenges, particularly in achieving profitability amid an early clinical-stage pipeline focused on neurodegenerative diseases. Additionally, the company faces multiple risks, including liquidity concerns, potential failures in clinical trials, regulatory approval hurdles, and competitive pressures, all of which contribute to a negative outlook on its stock performance.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.